Testosterone and Prostate Health: Have the Paradigms Truly Shifted?

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2020 Sep 15

PMID 32931422

Authors

Alvaro Morales

D Robert Siemens

Affiliations

Soon will be listed here.

References

Pastuszak A, Rodriguez K, Nguyen T, Khera M . Testosterone therapy and prostate cancer. Transl Androl Urol. 2017; 5(6):909-920. PMC: 5182214. DOI: 10.21037/tau.2016.08.17. View

Morgentaler A, Traish A . Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2008; 55(2):310-20. DOI: 10.1016/j.eururo.2008.09.024. View

Bhasin S, Cunningham G, Hayes F, Matsumoto A, Snyder P, Swerdloff R . Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(6):2536-59. DOI: 10.1210/jc.2009-2354. View

Rhoden E, Morgentaler A . Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003; 170(6 Pt 1):2348-51. DOI: 10.1097/01.ju.0000091104.71869.8e. View

Bellamri M, Turesky R . Dietary Carcinogens and DNA Adducts in Prostate Cancer. Adv Exp Med Biol. 2020; 1210:29-55. PMC: 7203629. DOI: 10.1007/978-3-030-32656-2_2. View

Denmeade S, Isaacs J . Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate. 2010; 70(14):1600-7. PMC: 4124628. DOI: 10.1002/pros.21196. View

Marks L, Mazer N, Mostaghel E, Hess D, Dorey F, Epstein J . Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006; 296(19):2351-61. DOI: 10.1001/jama.296.19.2351. View

Alanee S, El-Zawahry A, Dynda D, Dabaja A, McVary K, Karr M . A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. Prostate. 2018; 79(1):81-87. DOI: 10.1002/pros.23713. View

Shaneyfelt T, Husein R, Bubley G, Mantzoros C . Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol. 2000; 18(4):847-53. DOI: 10.1200/JCO.2000.18.4.847. View

10.

Aronson K, Wilson J, Hamel M, Diarsvitri W, Fan W, Woolcott C . Plasma organochlorine levels and prostate cancer risk. J Expo Sci Environ Epidemiol. 2009; 20(5):434-45. DOI: 10.1038/jes.2009.33. View

11.

Michaud J, Billups K, Partin A . Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015; 7(6):378-87. PMC: 4647137. DOI: 10.1177/1756287215597633. View

12.

Rodriguez K, Pastuszak A, Khera M . The Role of Testosterone Therapy in the Setting of Prostate Cancer. Curr Urol Rep. 2018; 19(8):67. DOI: 10.1007/s11934-018-0812-1. View

13.

Slater S, Oliver R . Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging. 2001; 17(6):431-9. DOI: 10.2165/00002512-200017060-00001. View

14.

Morales A, Connolly J, Bruce A . Androgen therapy in advanced carcinoma of the prostate. Can Med Assoc J. 1971; 105(1):71-2. PMC: 1931060. View

15.

Morgentaler A, Bruning 3rd C, DeWolf W . Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996; 276(23):1904-6. View

16.

Hoare D, Skinner T, Black A, Siemens D . Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer. Can Urol Assoc J. 2015; 9(3-4):122-7. PMC: 4455620. DOI: 10.5489/cuaj.2545. View

17.

Morales A . Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU Int. 2011; 107(9):1369-73. DOI: 10.1111/j.1464-410X.2011.10193.x. View

18.

Chuu C, Hiipakka R, Fukuchi J, Kokontis J, Liao S . Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res. 2005; 65(6):2082-4. DOI: 10.1158/0008-5472.CAN-04-3992. View

19.

Curran M, Bihrle 3rd W . Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology. 1999; 53(2):423-4. DOI: 10.1016/s0090-4295(98)00348-3. View

20.

Schweizer M, Antonarakis E, Wang H, Ajiboye A, Spitz A, Cao H . Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015; 7(269):269ra2. PMC: 4507510. DOI: 10.1126/scitranslmed.3010563. View